Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Dynamic Advisor Solutions LLC

Dynamic Advisor Solutions LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,156 shares of the biopharmaceutical company’s stock after selling 5,449 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Gilead Sciences were worth $5,279,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of GILD. nVerses Capital LLC acquired a new position in shares of Gilead Sciences during the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC boosted its stake in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter valued at $29,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 2nd quarter worth $33,000. Finally, Quarry LP acquired a new stake in shares of Gilead Sciences in the second quarter valued at $43,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock valued at $42,130,461 in the last 90 days. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Up 0.2 %

Shares of GILD stock opened at $93.07 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $115.99 billion, a PE ratio of 1,034.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The stock has a 50 day moving average of $91.74 and a 200-day moving average of $84.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.29 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Oppenheimer boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Truist Financial raised their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.